ClinicalTrials.gg
CompletedNCT01145638Updated Dec 3, 2015Results posted

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

A Phase 3 interventional study of iron isomaltoside 1000 and iron sulphate in Non-myeloid Malignancies and Chemotherapy Induced Anaemia, sponsored by Pharmacosmos A/S. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-03.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.

02

Conditions studied

  • Non-myeloid Malignancies
  • Chemotherapy Induced Anaemia

Browse trials for

Keywords

  • cancer
  • chemotherapy induced anaemia
  • iron
  • Patients with non-myeloid malignancies and Chemotherapy Induced Anaemia (CIA)
  • CIA
03

In context

Neoplasms

10,824 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 350 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women, aged more than 18 years.
  2. Subjects diagnosed with cancer (non-myeloid ) receiving chemotherapy at least 1 day prior to screening and who are going to receive at least two more chemotherapy cycles.
  3. \< 12 g/dL (7.4 mmol/L).
  4. TfS \<50%.
  5. Serum Ferritin \<800 ng/ml.
  6. An (ECOG) performance status of 0 to
  7. Willingness to participate after (including HIPAA, if applicable).

Exclusion criteria

Exclusion Criteria:

  1. Anemia caused primarily by other factors than CIA.
  2. IV or oral iron treatment within 4 weeks prior to screening visit.
  3. Erythropoietin treatment within 4 weeks prior to screening visit.
  4. Blood transfusion within 4 weeks prior to screening visit.
  5. Imminent expectation of blood transfusion on part of treating physician.
  6. Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
  7. Drug (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulfate).
  8. Known hypersensitivity to any in the drug products.
  9. Subjects with a history of multiple allergies.
  10. Decompensated liver cirrhosis or active hepatitis ( (ALAT) > 3 times upper normal limit).
  11. Active acute or chronic infections (assessed by clinical judgement and if deemed necessary by investigator supplied with white blood cells (WBC) and C-reactive protein (CRP)).
  12. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
  13. Pregnancy and nursing (To avoid pregnancy, women have to be (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
  14. Planned elective surgery during the study.
  15. Participation in any other clinical study (except chemotherapy protocol) within 3 months prior to screening.
  16. Known intolerance to oral iron treatment.
  17. Untreated B12 or folate deficiency.
  18. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    iron isomaltoside 1000

    Iron isomaltoside intravenously as bolus or infusion

    Drug: iron isomaltoside 1000

  • Active comparator
    iron sulphate

    oral iron sulphate twice a day

    Drug: iron sulphate

Interventions

  • intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose

    Also known as: Monofer

  • oral, 200 mg per day (100 mg bid),12 weeks

    Also known as: Ferroduretter

06

What researchers measure

Primary outcomes

  1. Change in Hb Concentration

    Time frame: Baseline week 4

Secondary outcomes

  1. Change in Hemoglobin From Baseline to Week 24

    Time frame: 24 weeks

07

Results

Posted Dec 3, 2015

Participant flow

Participant flow — Overall Study
MilestoneIron Isomaltoside 1000Iron Sulphate
Started231119
Completed14162
Not completed9057

Outcome measures

PrimaryChange in Hb Concentration
Time frame:
Baseline week 4
Reported as:
Mean · g/dL
Change in Hb Concentration
g/dLIron Isomaltoside 1000Iron Sulphate
Change in Hb Concentration0.48 (-4 to 4)0.44 (-2 to 4)
SecondaryChange in Hemoglobin From Baseline to Week 24
Time frame:
24 weeks
Reported as:
Mean · g/dL
Change in Hemoglobin From Baseline to Week 24
g/dLIron Isomaltoside 1000Iron Sulphate
Change in Hemoglobin From Baseline to Week 241.60 (-6.3 to 6.5)1.78 (-5.3 to 7.4)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iron Isomaltoside 1000—32/229 (14%)173/229 (75.5%)
Iron Sulphate—18/112 (16.1%)107/112 (95.5%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventIron Isomaltoside 1000Iron Sulphate
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/2297/112
AnaemiaBlood and lymphatic system disorders2/2292/112
Atrial fibrillationCardiac disorders3/2291/112
PancytopeniaBlood and lymphatic system disorders1/2291/112
Cardiac failureCardiac disorders1/2291/112
AscitesGastrointestinal disorders0/2291/112
AstheniaGeneral disorders1/2291/112
SepsisInfections and infestations0/2291/112
Unirary tract infectionInfections and infestations0/2291/112
HyperglycaemiaMetabolism and nutrition disorders0/2291/112
Most frequent other events
Showing 10 of 14
Most frequent other events
EventIron Isomaltoside 1000Iron Sulphate
AnaemiaBlood and lymphatic system disorders20/22912/112
LeukopeniaBlood and lymphatic system disorders12/22910/112
DiarrhoeaGastrointestinal disorders8/22910/112
Faeces discolouredGastrointestinal disorders1/2299/112
AlopeciaSkin and subcutaneous tissue disorders17/2299/112
AstheniaGeneral disorders18/2297/112
NauseaGastrointestinal disorders14/2298/112
VomitingGastrointestinal disorders16/2297/112
NeutropeniaBlood and lymphatic system disorders15/2296/112
ThrombocytopeniaBlood and lymphatic system disorders11/2297/112

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Iron Isomaltoside 1000Iron SulphateTotal
<=18 years000
Between 18 and 65 years187101288
>=65 years441862
Sex: Female, Male
Sex: Female, Male(Participants)Iron Isomaltoside 1000Iron SulphateTotal
Female15190241
Male8029109
Region of Enrollment
Region of Enrollment(participants)Iron Isomaltoside 1000Iron SulphateTotal
India13372205
Germany7310
Denmark314
Spain202
Poland401656
Russian Federation291847
Sweden538
United States12618
08

Study locations

1 site
  • Apollo Hospitals
    New Delhi, India
09

References and documents

Publications

  • Birgegard G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy. 2016 Apr;36(4):402-14. doi: 10.1002/phar.1729. Epub 2016 Apr 1. PubMed 26927900 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Apr 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2010
First posted
Jun 16, 2010
Start
Oct 2010
Primary completionActual
Apr 2014
CompletionActual
May 2014
Results first posted
Dec 3, 2015
Last update
Dec 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01145638
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Jun 16, 2010
Start date
Oct 2010
Primary completion
Apr 2014
Completion
May 2014
Results posted
Dec 3, 2015
Last update
Dec 3, 2015

Study contacts

Lars Lykke Thomsen, MD
study chair · Pharmacosmos A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion